Protocol Ledger

NCT07673029 · Phase III · RECRUITING

A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Interventional Phase III clinical trial protocol NCT07673029 sponsored by GeneQuantum Healthcare (Suzhou) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-01-10 Enrollment: 228 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07673029
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)228 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07673029
Protocol FieldVerified Registry Value
NCT IdentifierNCT07673029
Consolidated Lead SponsorGeneQuantum Healthcare (Suzhou) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment228 participants (ESTIMATED)
Registered Start Date2025-01-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI